CoChat

A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer

Open access
Gilmour, Alanna M., Abdulkhalek, Samar, Cheng, Timothy S.W., Alghamdi, Farah, Jayanth, Preethi, O’Shea, Leah K., Geen, Olivia, Arvizu, Luis A., Szewczuk, Myron R. · 2013 · Cellular Signalling
Cited by 89

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Epidermal growth factor (EGF)-induced EGFR tyrosine kinase receptor activation in cancer cell survival responses has become a strategic molecular-targeting clinical therapeutic intent, but the failures of these targeted approaches in the clinical setting demand alternate strategies. Here, we uncover a novel neuraminidase-1 (Neu1) and matrix metalloproteinase-9 (MMP-9) cross-talk in alliance with GPCR neuromedin B, which is essential for EGF-induced receptor activation and cellular signaling. Neu1 and MMP-9 form a complex with EGFR on the cell surface. Tamiflu (oseltamivir phosphate), anti-Neu1 antibodies, broad range MMP inhibitor galardin (GM6001), neuromedin B GPCR specific antagonist BIM-23127, the selective inhibitor of whole heterotrimeric G-protein complex BIM-46174 and MMP-9 specific inhibitor dose-dependently inhibited Neu1 activity associated with EGF stimulated 3T3-hEGFR cells. Tamiflu, anti-Neu1 antibodies and MMP9i attenuated EGFR phosphorylation associated with EGF-stimulated cells. Preclinical data provide the proof-of-evidence for a therapeutic targeting of Neu1 with Tamiflu in impeding human pancreatic cancer growth and metastatic spread in heterotopic xenografts of eGFP-MiaPaCa-2 tumors growing in RAGxCγ double mutant mice. Tamiflu-treated cohort exhibited a reduction of phosphorylation of EGFR-Tyr1173, Stat1-Tyr701, Akt-Thr308, PDGFRα-Tyr754 and NFκBp65-Ser311 but an increase in phospho-Smad2-Ser465/467 and -VEGFR2-Tyr1175 in the tumor lysates from the xenografts of human eGFP-MiaPaCa-2 tumor-bearing mice. The findings identify a novel promising alternate therapeutic treatment of human pancreatic cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cellsig.2013.08.008

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 89

Metadata

Authors
Gilmour, A. M., Abdulkhalek, S., Cheng, T. S. W., Alghamdi, F., Jayanth, P., O’Shea, L. K., Geen, O., Arvizu, L. A., & Szewczuk, M. R.
Venue
Cellular Signalling
Publisher
Elsevier BV
Published
2013-12
Volume
25
Issue
12
Pages
2587-2603
ISSN
0898-6568 (ISSN-L)
OpenAlex
W2051011074
Cited by
89
References
9
FWCI
3.00
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer. https://app.cochat.ai/papers/10.1016/j.cellsig.2013.08.008
The paper
Gilmour, A. M., Abdulkhalek, S., Cheng, T. S. W., Alghamdi, F., Jayanth, P., O’Shea, L. K., Geen, O., Arvizu, L. A., & Szewczuk, M. R. (2013). A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2013.08.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.